# Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

> **NCT01179776** · PHASE1,PHASE2 · COMPLETED · sponsor: **Thrombologic ApS** · enrollment: 16 (actual)

## Conditions studied

- Myocardial Infarct

## Interventions

- **DRUG:** Ilomedin
- **DRUG:** Placebo
- **DRUG:** Ilomedin
- **DRUG:** Ilomedin and standard low dose treatment

## Key facts

- **NCT ID:** NCT01179776
- **Lead sponsor:** Thrombologic ApS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2011-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01179776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01179776, "Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01179776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*